Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemodynamic effects of remimazolam in coronary heart disease patients undergoing non-cardiac surgery
ChiCTR2500102671Phase 4Not yet recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remimazolam in coronary arteriosclerosis (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoints: Blood pressure, Heart rate and 3 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2500102671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102671.